GVAX
- Generic Name
- GVAX
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Associated Conditions
- -
- Associated Therapies
- -
Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas
Early Phase 1
Completed
- Conditions
- Pancreatic Cancer
- Interventions
- First Posted Date
- 2017-05-15
- Last Posted Date
- 2025-01-09
- Lead Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Target Recruit Count
- 11
- Registration Number
- NCT03153410
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath